Chest:全国肺部筛查试验低剂量CT筛查后的患者水平轨迹和预后

2019-07-11 xiangting MedSci原创

这项研究提供了来自NLST重要的患者水平数据,可用于指导共同决策。

共同决策是肺癌低剂量计算机断层扫描(LDCT)筛查的基本要素。了解全国肺部筛查试验(NLST)的患者水平预后对于有效地将筛查的风险和益处传达给患者至关重要。

研究人员对NLST收集的数据进行了二次分析。确定了NLST中进行的每个LDCT的结果(下游评估、并发症、肺癌诊断),并将随机进行LDCT筛查人员的测试水平结果与计算的患者水平结果进行比较。为了评估COPD对患者预后的影响,研究比较了伴和不伴COPD患者的结局。

在75,138次LDCT扫描中,14.2%进行了诊断性研究,1.5%进行了侵入性手术,0.3%的LDCT扫描导致了手术相关并发症,0.1%导致严重并发症。接受LDCT筛查的24,453名患者中,30.5%接受了诊断性研究,4.2%接受了侵入性治疗,其中0.9%的筛查患者出现了手术相关并发症,0.3%出现严重并发症。COPD患者(由自我报告定义)更可能需要进行诊断性研究(aOR 1.29,p<0.01)和侵入性手术(aOR 1.41,p<0.01),其出现并发症(调整OR 1.83,p<0.01)和严重并发症的可能性更大(aOR 1.78,p=0.01)。COPD患者也更可能被诊断为肺癌(aOR 1.43,p<0.01)。

这项研究提供了来自NLST重要的患者水平数据,可用于指导共同决策。在一些患者中,筛查的风险-收益比有明显差异,例如COPD患者,其筛查的风险和收益均升高。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2051413, encodeId=137d2051413c2, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Jul 15 01:51:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929570, encodeId=2cf819295e0f4, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Thu Feb 20 05:51:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768901, encodeId=36de1e68901b0, content=<a href='/topic/show?id=351454e3d6' target=_blank style='color:#2F92EE;'>#CT筛查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5473, encryptionId=351454e3d6, topicName=CT筛查)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93a637925369, createdName=ms6747015003810650, createdTime=Mon Oct 21 00:51:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803795, encodeId=bf981803e9558, content=<a href='/topic/show?id=d46be594058' target=_blank style='color:#2F92EE;'>#筛查试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75940, encryptionId=d46be594058, topicName=筛查试验)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/vLodSSFTQLpHtfwJicWJibSWH7pbiauxvpCMvQIv0N9Oes8vHkDkCIW2HNDkt7icUq3RCZiaDcHR9Rap17fFySRbiaFg/132, createdBy=9f202500205, createdName=ms3297076796458174, createdTime=Tue Jun 16 02:51:00 CST 2020, time=2020-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423978, encodeId=0b2014239e8f1, content=<a href='/topic/show?id=3f482616064' target=_blank style='color:#2F92EE;'>#低剂量CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26160, encryptionId=3f482616064, topicName=低剂量CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8c83876884, createdName=xlxchina, createdTime=Sat Jul 13 02:51:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480549, encodeId=214f148054996, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Sat Jul 13 02:51:00 CST 2019, time=2019-07-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2051413, encodeId=137d2051413c2, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Jul 15 01:51:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929570, encodeId=2cf819295e0f4, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Thu Feb 20 05:51:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768901, encodeId=36de1e68901b0, content=<a href='/topic/show?id=351454e3d6' target=_blank style='color:#2F92EE;'>#CT筛查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5473, encryptionId=351454e3d6, topicName=CT筛查)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93a637925369, createdName=ms6747015003810650, createdTime=Mon Oct 21 00:51:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803795, encodeId=bf981803e9558, content=<a href='/topic/show?id=d46be594058' target=_blank style='color:#2F92EE;'>#筛查试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75940, encryptionId=d46be594058, topicName=筛查试验)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/vLodSSFTQLpHtfwJicWJibSWH7pbiauxvpCMvQIv0N9Oes8vHkDkCIW2HNDkt7icUq3RCZiaDcHR9Rap17fFySRbiaFg/132, createdBy=9f202500205, createdName=ms3297076796458174, createdTime=Tue Jun 16 02:51:00 CST 2020, time=2020-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423978, encodeId=0b2014239e8f1, content=<a href='/topic/show?id=3f482616064' target=_blank style='color:#2F92EE;'>#低剂量CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26160, encryptionId=3f482616064, topicName=低剂量CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8c83876884, createdName=xlxchina, createdTime=Sat Jul 13 02:51:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480549, encodeId=214f148054996, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Sat Jul 13 02:51:00 CST 2019, time=2019-07-13, status=1, ipAttribution=)]
    2020-02-20 Smile2680
  3. [GetPortalCommentsPageByObjectIdResponse(id=2051413, encodeId=137d2051413c2, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Jul 15 01:51:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929570, encodeId=2cf819295e0f4, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Thu Feb 20 05:51:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768901, encodeId=36de1e68901b0, content=<a href='/topic/show?id=351454e3d6' target=_blank style='color:#2F92EE;'>#CT筛查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5473, encryptionId=351454e3d6, topicName=CT筛查)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93a637925369, createdName=ms6747015003810650, createdTime=Mon Oct 21 00:51:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803795, encodeId=bf981803e9558, content=<a href='/topic/show?id=d46be594058' target=_blank style='color:#2F92EE;'>#筛查试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75940, encryptionId=d46be594058, topicName=筛查试验)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/vLodSSFTQLpHtfwJicWJibSWH7pbiauxvpCMvQIv0N9Oes8vHkDkCIW2HNDkt7icUq3RCZiaDcHR9Rap17fFySRbiaFg/132, createdBy=9f202500205, createdName=ms3297076796458174, createdTime=Tue Jun 16 02:51:00 CST 2020, time=2020-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423978, encodeId=0b2014239e8f1, content=<a href='/topic/show?id=3f482616064' target=_blank style='color:#2F92EE;'>#低剂量CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26160, encryptionId=3f482616064, topicName=低剂量CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8c83876884, createdName=xlxchina, createdTime=Sat Jul 13 02:51:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480549, encodeId=214f148054996, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Sat Jul 13 02:51:00 CST 2019, time=2019-07-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2051413, encodeId=137d2051413c2, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Jul 15 01:51:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929570, encodeId=2cf819295e0f4, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Thu Feb 20 05:51:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768901, encodeId=36de1e68901b0, content=<a href='/topic/show?id=351454e3d6' target=_blank style='color:#2F92EE;'>#CT筛查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5473, encryptionId=351454e3d6, topicName=CT筛查)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93a637925369, createdName=ms6747015003810650, createdTime=Mon Oct 21 00:51:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803795, encodeId=bf981803e9558, content=<a href='/topic/show?id=d46be594058' target=_blank style='color:#2F92EE;'>#筛查试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75940, encryptionId=d46be594058, topicName=筛查试验)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/vLodSSFTQLpHtfwJicWJibSWH7pbiauxvpCMvQIv0N9Oes8vHkDkCIW2HNDkt7icUq3RCZiaDcHR9Rap17fFySRbiaFg/132, createdBy=9f202500205, createdName=ms3297076796458174, createdTime=Tue Jun 16 02:51:00 CST 2020, time=2020-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423978, encodeId=0b2014239e8f1, content=<a href='/topic/show?id=3f482616064' target=_blank style='color:#2F92EE;'>#低剂量CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26160, encryptionId=3f482616064, topicName=低剂量CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8c83876884, createdName=xlxchina, createdTime=Sat Jul 13 02:51:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480549, encodeId=214f148054996, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Sat Jul 13 02:51:00 CST 2019, time=2019-07-13, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2051413, encodeId=137d2051413c2, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Jul 15 01:51:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929570, encodeId=2cf819295e0f4, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Thu Feb 20 05:51:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768901, encodeId=36de1e68901b0, content=<a href='/topic/show?id=351454e3d6' target=_blank style='color:#2F92EE;'>#CT筛查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5473, encryptionId=351454e3d6, topicName=CT筛查)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93a637925369, createdName=ms6747015003810650, createdTime=Mon Oct 21 00:51:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803795, encodeId=bf981803e9558, content=<a href='/topic/show?id=d46be594058' target=_blank style='color:#2F92EE;'>#筛查试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75940, encryptionId=d46be594058, topicName=筛查试验)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/vLodSSFTQLpHtfwJicWJibSWH7pbiauxvpCMvQIv0N9Oes8vHkDkCIW2HNDkt7icUq3RCZiaDcHR9Rap17fFySRbiaFg/132, createdBy=9f202500205, createdName=ms3297076796458174, createdTime=Tue Jun 16 02:51:00 CST 2020, time=2020-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423978, encodeId=0b2014239e8f1, content=<a href='/topic/show?id=3f482616064' target=_blank style='color:#2F92EE;'>#低剂量CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26160, encryptionId=3f482616064, topicName=低剂量CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8c83876884, createdName=xlxchina, createdTime=Sat Jul 13 02:51:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480549, encodeId=214f148054996, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Sat Jul 13 02:51:00 CST 2019, time=2019-07-13, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2051413, encodeId=137d2051413c2, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Jul 15 01:51:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929570, encodeId=2cf819295e0f4, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Thu Feb 20 05:51:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768901, encodeId=36de1e68901b0, content=<a href='/topic/show?id=351454e3d6' target=_blank style='color:#2F92EE;'>#CT筛查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5473, encryptionId=351454e3d6, topicName=CT筛查)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93a637925369, createdName=ms6747015003810650, createdTime=Mon Oct 21 00:51:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803795, encodeId=bf981803e9558, content=<a href='/topic/show?id=d46be594058' target=_blank style='color:#2F92EE;'>#筛查试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75940, encryptionId=d46be594058, topicName=筛查试验)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/vLodSSFTQLpHtfwJicWJibSWH7pbiauxvpCMvQIv0N9Oes8vHkDkCIW2HNDkt7icUq3RCZiaDcHR9Rap17fFySRbiaFg/132, createdBy=9f202500205, createdName=ms3297076796458174, createdTime=Tue Jun 16 02:51:00 CST 2020, time=2020-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423978, encodeId=0b2014239e8f1, content=<a href='/topic/show?id=3f482616064' target=_blank style='color:#2F92EE;'>#低剂量CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26160, encryptionId=3f482616064, topicName=低剂量CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8c83876884, createdName=xlxchina, createdTime=Sat Jul 13 02:51:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480549, encodeId=214f148054996, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Sat Jul 13 02:51:00 CST 2019, time=2019-07-13, status=1, ipAttribution=)]

相关资讯

Nature:中科院研究,有望抑制肺癌转移!

在由中科院上海生化细胞所杨巍维博士与中国科学院大连化学物理研究所李国辉博士研究组合作发表于《Nature》的一篇研究中,研究者们进一步探索了癌症转移的机制,并为预防肿瘤转移提供一些新的思路。

肺癌研究进展 再不知道你就OUT了!

2019年7月4日至7日,中国临床肿瘤学年度进展研讨会(Best of CSCO, BOC)暨Best of ASCO 2019 China(BOA)在西安召开。7月6日上午的肺癌专场下半场主要由广东省人民医院的钟文昭教授和上海市肺科医院的任胜祥教授分别对三项重磅临床研究进行介绍,内容涵盖了:经表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)治疗耐药后合并MET阳性的非小细胞肺癌(NSCL

Lancet Oncol:满足 vs 不满足USPSTF筛查标准的肺癌患者,5年生存率相似

美国预防服务工作小组(USPSTF)推荐对年龄55-80岁,吸烟史达到30包年及以上或戒烟时间少于15年的人群进行肺癌筛查。然而,临床上很多肺癌患者并不符合这一筛查标准,如年轻肺癌患者和长期戒烟者。近期Lancet Oncology杂志发布的一项研究对满足 vs 不满足USPSTF筛查标准的肺癌患者进行生存对比。

陆舜教授:促进亚太地区肺癌诊疗水平的提高,中国专家任重而道远

浴兰时节,菖蒲酒美,契阔谈宴恰逢时。践行“一带一路”倡议,借助区域合作平台,积极拓展中国与亚太国家和地区的科学交流与合作,不遗余力推动“中国健康创新模式”,2019年6月13—14日,阿斯利康泛亚肺癌高峰论坛(Pan-Asia Lung Cancer Summit)隆重召开。会议邀请到韩国延世大学医学院的Byoung Chul Cho教授、美国Levine癌症研究所的Edward S.Kim教授,

Nature:杨巍维教授发现尿酸代谢关键酶能抑制肺癌转移

6月26日,中国科学院生物化学与细胞生物学研究所杨巍维(YANG Weiwei)博士与中国科学院大连化学物理研究所李国辉博士领导的研究小组在《Nature》杂志上发表了一项研究报告:“尿苷二磷酸葡萄糖(UDP-glucose)不仅是尿酸代谢中的代谢中间产物,而且它还有一个新功能——加速SNAI1 mRNA衰变阻止肺癌转移。”这一发现很重要,因为肺癌是中国乃至世界最主要的癌症杀手,估计95%的癌症死

抗肿瘤药物处方审核专家共识—肺癌

为了进一步规范肿瘤的药物治疗,促进临床合理用药,改善肺癌患者的预后,由国家癌症中心、国家肿瘤质控中心药事质控专家委员会牵头,中国抗癌协会肿瘤临床药学专业委员会、中国药师协会肿瘤药师分会共同组织全国药学专家,根据《医疗机构处方审核规范》及抗肿瘤药物管理相关规定,结合目前国内肿瘤专科药师临床处方审核的实践经验,制定了《肺癌抗肿瘤药物处方审核专家共识》。 本共识首次提出运用“六步法”进行抗肿瘤药物处方审